Health
Molecular Data Inc. intends to further upgrade its digital tools using Blockchain
SHANGHAI, April 1, 2021 /PRNewswire/ -- Molecular Data Inc. ("Molecular Data" or the "Company") (Nasdaq: MKD), a leading technology-driven platform inChina's chemical industry, announced that it has signed a cooperation agreement with Dalian Lianhua Chemical Co., Ltd. ("Dalian Lianhua"), a leadin...
2021-04-01 19:00
2932
Jolly Good Newly Establishes CBT VR Specialist Department with Clinical Psychiatrists
TOKYO, April 1, 2021 /PRNewswire/ -- Leading Japanese medical VR company Jolly
Good Inc. has recently established a specialized DTx Division to develop
digital therapeutics (hereinafter "DTx") using VR and AI technologies.
Logo: https://kyodonewsprwire.jp/img/202103313079-O1-CAsOT26u
2021-04-01 16:00
1704
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib
* Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma * Linperlisib has a differentiated and well manageable safety profile SHANGHAI ,March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Y...
2021-04-01 14:09
1789
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-03-31 20:45
3556
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
2021-03-31 20:30
2027
Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enr...
2021-03-31 20:00
10115
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market
SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...
2021-03-31 19:30
2448
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth
SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...
2021-03-31 09:11
3770
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...
2021-03-31 09:00
2434
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
2021-03-30 20:30
3275
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
2008
Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Pivotal study to evaluate the use of novel liquid embolic versus standard of care in treating malignant and benign hypervascular tumors BEDFORD, Mass., March 30, 2021 /PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embol...
2021-03-30 19:02
1206
TurtleTree Scientific and JSBiosciences enter into a strategic partnership for the development of cell culture media and contract manufacturing services
SINGAPORE, March 29, 2021 /PRNewswire/ -- JSBiosciences (hereinafter referred to as "JSBio") has just announced a partnership with TurtleTree Scientific (hereinafter referred to as "TTS"). Both parties have signed a letter of intent to collaborate in the development of cell culture media at a com...
2021-03-30 06:00
2082
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...
2021-03-30 04:30
5134
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
2021-03-30 04:10
3962
Fosun Pharma Announces 2020 Annual Results
Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY toRMB2,718 Million SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (...
2021-03-30 00:38
5113
HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....
2021-03-29 22:00
3410
Tigermed Reports 2020 Annual Results With Solid Growth
HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...
2021-03-29 21:21
4661
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results
BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after itsHong Kong listing. By the end ofDecember 31, 2020, its annual revenue was 486 million yuan and R&D expenses exceeded230 million yuan and increased 66% compared to 2019....
2021-03-29 13:11
3811
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated...
2021-03-28 11:04
2832
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00